Treatment of Advanced Renal-Cell Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature.Frontiers in endocrinology · 2020
   Article
2. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.Cancer immunology research · 2018
   Article
3. A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy.Oncotarget · 2017
   Article
4. Modulation of cabozantinib efficacy by the prostate tumor microenvironment.Oncotarget · 2017
   Article
5. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.Urologic oncology · 2017
   Review
6. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.Oncotarget · 2017
   Article
7. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.Drug design, development and therapy · 2017
   Review
8. A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells.Nature communications · 2016
   Article

Corrections and comments

• Comment on
  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.2015
• Comment on
  Treatment of Advanced Renal-Cell Carcinoma.2016
• Comment on
  Treatment of Advanced Renal-Cell Carcinoma.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as